Dairy Dialog podcast 12: DSM cultures and HMOs for infant formula

By Jim Cornall contact

- Last updated on GMT

Related tags: Dsm food specialties, Yoghurt, Yogurt, HMO, oligosaccharides, Infant formula

This week’s Dairy Dialog podcast heads to Belgium and the Netherlands for interviews on human milk oligosaccharides (HMO) and yogurt cultures.

DSM launches new culture for stirred yogurts

DSM Food Specialties has launched DelvoFresh YS-140 culture for stirred yogurts to produce what the company says is “a creamy yogurt with a velvety mouthfeel and mild taste that consumers are after in today’s market.”

The new culture has a fast fermentation time and limited post-acidification at 5°C, meaning it maintains a mild taste during its entire shelf life. It is suitable for all types of stirred yogurts, including flavored or plain yogurt, as well as yogurts with added indulgent flavors such as fruit.

DairyReporter talks to Rolando Saltini, business manager for fermented milk products at DSM.

Saltini said, “Yogurt has quickly become a mainstay in the diets of many people​. Yogurt can be a healthy breakfast, a high-protein pre- or post-workout snack, and it can be an indulgent snack or dessert. Our new DelvoFresh YS-140 is the culture in our range with the best balance between high creaminess and mild taste, delivering to the desire for more indulgence and enabling more yogurt moments in the day.”

Inbiose secures €4m in debt financing

Belgian biotech company Inbiose has entered into a €4m ($4.6m) debt agreement with BNP Paribas Fortis, one of the largest banks in Belgium.

The arrangement gives Inbiose access to non-dilutive financing to continue the development of its portfolio of HMOs and to drive them towards regulatory approval and market launch.

Last month Inbiose announced it is fast tracking seven HMOs from its portfolio for use in infant formula and health markets. Inbiose is looking to partner with industry segment leaders to accelerate registration and commercialization of HMOs into baby food, cosmetics, nutrition, pharma, dietary supplements and therapeutics.

In 2016, Inbiose entered into a collaboration with DuPont Nutrition & Health on fucosyllactose for human nutrition.

The product received the NutraIngredients-USA “Ingredient of the Year Award 2018” and is currently sold under the brand name Care4UTM both in infant formula as well as in health products.

Paul Decraemer, CFO, said, “This financing illustrates the confidence in our business case and its growth trajectory. Combined with the current cash balance, this debt facility enhances our flexibility to execute on the many opportunities we identify in the specialty carbohydrates market.”

Professor Wim Soetaert, CEO and chairman, said, “As we move into 2019, we will continue to evaluate all strategic opportunities to maximize the value of our state of the art GlycoActives technology platform. Securing debt finance helps us to achieve this goal.”

Extended offering

Inbiose extended its offering to seven HMOs for which efficient processes become available for large-scale manufacturing and commercialization.

The announcement marked the completion of a five-year strategic investment in developing the company’s GlycoActives platform to quickly develop cost-effective industrial fermentation processes to produce its ingredients.

In addition to fucosylated molecules 2’-fucosyllactose, 3-fucosyllactose and difucosyllactose, Inbiose technology is enabling large-scale production of Lacto-N-neo-tetraose (LNnT) and Lacto-N-tetraose (LNT) as well as the acidic HMOs 6’-sialyllactose (6’SL) and 3’-sialyllactose (3’SL).

Inbiose said the commercial availability of these HMOs will bring new opportunities to further improve infant milk formula and to get closer to the gold standard, human breast milk.

DairyReporter talked to Soetaert and the company’s chief commercial officer, Wesley Carpentier.

Related products

show more

Human Bifidobacteria, selected by Mother’s milk

Human Bifidobacteria, selected by Mother’s milk

Morinaga Milk Industry Co., Ltd. | 13-Sep-2018 | Technical / White Paper

Health promoting traits of Bifidobacteria are well-known around the world and its effect is strain-specific, however, whether the residential origin of...

Omegavie® DHA algae Capsules

Omegavie® DHA algae Capsules

POLARIS | 23-Aug-2018 | Application Note

Omegavie® DHA algae capsules is a real opportunity to consume high-performing Omega-3 DHA 100% vegan, natural, sustainable, GMO- and allergen-free. Designed...

Related suppliers

comments

Post your comment

We will not publish your email address on the website

These comments have not been moderated. You are encouraged to participate with comments that are relevant to our news stories. You should not post comments that are abusive, threatening, defamatory, misleading or invasive of privacy. For the full terms and conditions for commenting see clause 7 of our Terms and Conditions ‘Participating in Online Communities’. These terms may be updated from time to time, so please read them before posting a comment. Any comment that violates these terms may be removed in its entirety as we do not edit comments. If you wish to complain about a comment please use the "REPORT ABUSE" button or contact the editors.

Follow us

Featured Events

View more

Products

View more

Webinars